^
Association details:
| Biomarker: | CD20 positive |
|---|---|
| Cancer: | Burkitt Lymphoma |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
12/02/2021
Excerpt:
RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of...Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) (1.1)...Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy.
Secondary therapy:
Chemotherapy
Source:
Title:
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer
Excerpt:
...- Histologically or immunophenotypically proven CD20-positive B-cell lymphoproliferative disorder...
Trial ID:
Source:
Title:
Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
Excerpt:
...- Tumors must be CD20 positive...
Trial ID:
More C2 evidence
Source:
Title:
To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma
Excerpt:
...CD 20 positive patients with Non-Hodgkin's lymphoma who are planned to receive anticancer treatment with rituximab based chemotherapy and A....
Trial ID:
Source:
Title:
Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL
Excerpt:
...- Immunohistochemistry showing CD20 positivity...
Trial ID:
